Stockreport

Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma [Yahoo! Finance]

Y-mAbs Therapeutics, Inc.  (YMAB) 
Last y-mabs therapeutics, inc. earnings: 11/13 04:01 pm Check Earnings Report
PDF company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced [Read more]